Arbutus Biopharma (ABUS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.22, -1.63% vs the prior close of $4.29.
- Volume 4.54M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ABUS dips 1.6% to $4.22. Closed at $4.22, -1.63% vs the prior close of $4.29. Day range $4.18–$4.29, opened at $4.29.
ABUS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ABUS dips 1.6% to $4.22
- Closed at $4.22, -1.63% vs the prior close of $4.29. Day range $4.18–$4.29, opened at $4.29.
- Volume was 4.54M shares, 0.8x its 50-day average of 5.71M.
- Price is -12.2% vs its 50-day average ($4.81) and -6.6% vs its 200-day average ($4.52).
- 52-week range $3.50–$5.45; today's close sits at 37% of that range, 22.6% below the 52-week high.
Oct 15, 2026 — ABUS rises 2.4% to $4.29
- Closed at $4.29, +2.39% vs the prior close of $4.19. Day range $4.22–$4.30, opened at $4.23.
- Volume was 2.28M shares, 0.4x its 50-day average of 5.70M — lighter than usual.
- Price is -10.8% vs its 50-day average ($4.81) and -5.1% vs its 200-day average ($4.52).
- 52-week range $3.50–$5.45; today's close sits at 41% of that range, 21.3% below the 52-week high.
Oct 14, 2026 — ABUS rises 1.9% to $4.19
- Closed at $4.19, +1.95% vs the prior close of $4.11. Day range $4.05–$4.25, opened at $4.07.
- Volume was 2.43M shares, 0.4x its 50-day average of 5.67M — lighter than usual.
- Price is -13.0% vs its 50-day average ($4.82) and -7.4% vs its 200-day average ($4.52).
- 52-week range $3.50–$5.45; today's close sits at 35% of that range, 23.1% below the 52-week high.
Oct 13, 2026 — ABUS dips 1.0% to $4.11, a 6-month low
- Closed at $4.11, -0.96% vs the prior close of $4.15. Day range $4.05–$4.16, opened at $4.13.
- Volume was 3.48M shares, 0.6x its 50-day average of 5.63M.
- Price is -14.8% vs its 50-day average ($4.82) and -9.2% vs its 200-day average ($4.53).
- 52-week range $3.50–$5.45; today's close sits at 31% of that range, 24.6% below the 52-week high.
Oct 12, 2026 — ABUS dips 1.7% to $4.15, a 3-month low
- Closed at $4.15, -1.66% vs the prior close of $4.22. Day range $4.12–$4.23, opened at $4.20.
- Volume was 2.34M shares, 0.4x its 50-day average of 5.61M — lighter than usual.
- Price is -14.0% vs its 50-day average ($4.83) and -8.4% vs its 200-day average ($4.53).
- 52-week range $3.50–$5.45; today's close sits at 33% of that range, 23.9% below the 52-week high.
Oct 9, 2026 — ABUS rises 1.0% to $4.22
- Closed at $4.22, +0.96% vs the prior close of $4.18. Day range $4.13–$4.27, opened at $4.17.
- Volume was 3.15M shares, 0.6x its 50-day average of 5.56M — lighter than usual.
- Price is -12.7% vs its 50-day average ($4.83) and -6.9% vs its 200-day average ($4.53).
- 52-week range $3.50–$5.45; today's close sits at 37% of that range, 22.6% below the 52-week high.
Oct 8, 2026 — ABUS dips 2.6% to $4.18, a 3-month low, 3 down days in a row
- Closed at $4.18, -2.56% vs the prior close of $4.29. Day range $4.05–$4.30, opened at $4.22.
- Volume was 4.85M shares, 0.9x its 50-day average of 5.50M.
- Price is -13.6% vs its 50-day average ($4.84) and -7.8% vs its 200-day average ($4.54).
- 52-week range $3.50–$5.45; today's close sits at 35% of that range, 23.3% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ABUS slides 4.2% to $4.29, a 1-month low
- Closed at $4.29, -4.24% vs the prior close of $4.48. Day range $4.28–$4.48, opened at $4.46.
- Volume was 4.79M shares, 0.9x its 50-day average of 5.42M.
- Price is -11.3% vs its 50-day average ($4.84) and -5.4% vs its 200-day average ($4.54).
- 52-week range $3.50–$5.45; today's close sits at 41% of that range, 21.3% below the 52-week high.
Oct 6, 2026 — ABUS slides 4.1% to $4.48
- Closed at $4.48, -4.07% vs the prior close of $4.67. Day range $4.43–$4.67, opened at $4.67.
- Volume was 8.26M shares, 1.6x its 50-day average of 5.28M.
- Price is -7.4% vs its 50-day average ($4.84) and -1.3% vs its 200-day average ($4.54).
- 52-week range $3.50–$5.45; today's close sits at 50% of that range, 17.8% below the 52-week high.
Oct 5, 2026 — ABUS jumps 4.9% to $4.67
- Closed at $4.67, +4.94% vs the prior close of $4.45. Day range $4.41–$4.80, opened at $4.45.
- Volume was 6.18M shares, 1.2x its 50-day average of 5.17M.
- Price is -3.5% vs its 50-day average ($4.84) and +2.9% vs its 200-day average ($4.54).
- 52-week range $3.50–$5.45; today's close sits at 60% of that range, 14.3% below the 52-week high.
Oct 2, 2026 — ABUS dips 2.4% to $4.45, a 1-month low
- Closed at $4.45, -2.41% vs the prior close of $4.56. Day range $4.38–$4.68, opened at $4.55.
- Volume was 8.99M shares, 1.8x its 50-day average of 5.02M.
- Price is -7.9% vs its 50-day average ($4.83) and -2.0% vs its 200-day average ($4.54).
- 52-week range $3.50–$5.45; today's close sits at 49% of that range, 18.3% below the 52-week high.
ABUS latest news & SEC filings
Every SEC filing by or about ABUS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Beardsley Robert A returned to the company 17,948 shares at $5.00 (≈$89.74K) on Oct 1, 2026; now holds 14,328
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Nguyen Tuan returned to the company 48,081 shares at $5.00 (≈$240.41K) on Oct 1, 2026; now holds 111,882
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sawhney Roger returned to the company 17,142 shares at $5.00 (≈$85.71K) on Oct 1, 2026; now holds 13,683
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Androski Lindsay returned to the company 24,655 shares at $5.00 (≈$123.28K) on Oct 1, 2026; now holds 47,682
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Roivant Sciences Ltd. returned to the company 8,967,383 shares at $5.00 (≈$44.84M) on Oct 1, 2026; now holds 29,880,079
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form SC TO-I/A — SC TO-I/A filing
SC TO-I/A filing
Sep 30, 2026 · Form SC TO-I/A — SC TO-I/A filing
SC TO-I/A filing
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Androski Lindsay converted options/RSUs into 116,408 shares at $3.20 (≈$372.51K) on Sep 18, 2026; now holds 144,408
- Androski Lindsay converted options/RSUs into 10,456 shares at $4.39 (≈$45.90K) on Sep 18, 2026; now holds 154,864
- Androski Lindsay had withheld for taxes 82,527 shares at $5.07 (≈$418.41K) on Sep 18, 2026; now holds 72,337
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 24, 2026 · Form SC TO-I — SC TO-I filing
SC TO-I filing
Aug 21, 2026 · Form SC TO-C — SC TO-C filing
SC TO-C filing
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ABUS
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 23, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.14% (largest 4.9%).
- Liquidity: about 8.13M shares (≈$34.30M) trade per day on average.
- 52-week position: $4.22 vs a range of $3.50–$5.45 (37% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 21, 2026; 10-Q Aug 12, 2026; 8-K Aug 12, 2026.
- Share count: 197.85M shares outstanding (Aug 10, 2026), +3.2% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ABUS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.29 | 4.29 | 4.18 | 4.22 | 4.54M |
| Oct 15, 2026 | 4.23 | 4.30 | 4.22 | 4.29 | 2.28M |
| Oct 14, 2026 | 4.07 | 4.25 | 4.05 | 4.19 | 2.43M |
| Oct 13, 2026 | 4.13 | 4.16 | 4.05 | 4.11 | 3.48M |
| Oct 12, 2026 | 4.20 | 4.23 | 4.12 | 4.15 | 2.34M |
| Oct 9, 2026 | 4.17 | 4.27 | 4.13 | 4.22 | 3.15M |
| Oct 8, 2026 | 4.22 | 4.30 | 4.05 | 4.18 | 4.85M |
| Oct 7, 2026 | 4.46 | 4.48 | 4.28 | 4.29 | 4.79M |
| Oct 6, 2026 | 4.67 | 4.67 | 4.43 | 4.48 | 8.26M |
| Oct 5, 2026 | 4.45 | 4.80 | 4.41 | 4.67 | 6.18M |
| Oct 2, 2026 | 4.55 | 4.68 | 4.38 | 4.45 | 8.99M |
| Oct 1, 2026 | 4.77 | 4.78 | 4.51 | 4.56 | 16.12M |
| Sep 30, 2026 | 4.68 | 4.95 | 4.68 | 4.78 | 16.88M |
| Sep 29, 2026 | 4.86 | 4.89 | 4.67 | 4.69 | 17.56M |
| Sep 28, 2026 | 4.84 | 4.88 | 4.80 | 4.86 | 11.67M |
| Sep 25, 2026 | 4.89 | 4.93 | 4.84 | 4.85 | 16.88M |
| Sep 24, 2026 | 4.85 | 4.89 | 4.80 | 4.88 | 6.26M |
| Sep 23, 2026 | 5.01 | 5.02 | 4.84 | 4.85 | 10.84M |
| Sep 22, 2026 | 5.02 | 5.05 | 5.00 | 5.01 | 10.49M |
| Sep 21, 2026 | 5.03 | 5.07 | 4.99 | 5.00 | 4.56M |
About Arbutus Biopharma
Arbutus Biopharma (ABUS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WARMINSTER, PA. State of incorporation: British Columbia, Canada. Fiscal year ends December 31. SEC CIK 1447028.
ABUS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Lindsay Androski | President and CEO | Sep 23, 2026 |
| Robert A Beardsley | Director | Sep 23, 2026 |
| Roger Sawhney | Director | Sep 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Lindsay Androski | President and CEO | Sep 23, 2026 |
| Tuan Nguyen | Chief Financial Officer | Sep 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
ABUS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $14.08M | $-33.50M | -0.17 | $-39.64M |
| Dec 31, 2024 | $6.17M | $-69.92M | -0.38 | $-64.85M |
| Dec 31, 2023 | $18.14M | $-72.85M | -0.44 | $-85.94M |
| Dec 31, 2022 | $39.02M | $-69.46M | -0.46 | $-35.36M |
| Dec 31, 2021 | $10.99M | $-76.25M | -0.83 | $-67.53M |
Latest balance sheet: total assets $71.72M, total liabilities $12.52M, cash $68.72M (as of Dec 31, 2013).
ABUS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $4.59 |
| May 13, 2026 | 8-K Item 2.02 (results) | $4.31 |
| Mar 23, 2026 | 8-K Item 2.02 (results) | $4.42 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $4.56 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $3.47 |
| May 14, 2025 | 8-K Item 2.02 (results) | $3.16 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $3.27 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $3.35 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $3.92 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ABUS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.